Calitii awarded contract to implement ServiceNow IT service management at BridgeBio

Calitii, a global technology company, has secured an agreement with BridgeBio, a biopharmaceutical company, to implement ServiceNow’s IT service management (ITSM) platform across its infrastructure. Patrick O’Connor, CEO at Calitii said: “We are excited to partner with BridgeBio on this greenfield ServiceNow ITSM implementation, and are committed to helping them achieve the full value of their investment, delivering enhanced operational efficiencies and productivity across their business.” Nick Keenan, SVP, Head of IT at BridgeBio said: “We are pleased to have appointed Calitii to integrate ServiceNow across our operations as part of our strategic growth plans, and we look forward to leveraging Calitii’s IT expertise in the biotechnology and pharmaceutical sectors.”  With operations in the UK, US, Australia and Ireland, Calitii specialises in integrating ServiceNow’s ITSM platform and AI capabilities for large-scale enterprises, driving digital transformation and operational efficiencies to achieve real business outcomes.  It has extensive experience working with multi-national biotechnology and pharmaceutical companies.   About Calitii  
Calitii is a global technology company and ServiceNow implementation partner focused on delivering critical change at scale for enterprises operating within highly regulated markets. Combining ServiceNow excellence, world-class business understanding and enterprise architecture capabilities, Calitii utilises uniquely experienced practitioner teams to drive effective change across business silos, transforming operational efficiencies and agility for large scale enterprises. For more information visit calitii.com and follow via LinkedIn and X.    About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow via LinkedIn, Twitter and Facebook.